Q-omics provides the consensus-scored CDK15 profile across patient tissues and cancer cell-line models. CDK15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CDK15 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, CDK15 RNA expression shows 18,479 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, LUAD, and BRCA as cancer lineages where CDK15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK15 survival associations across molecular data types. CDK15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK15 RNA expression–survival associations across cancer types. High CDK15 expression shows unfavorable associations in BLCA and MESO, but favorable associations in UVM, LUAD, ESCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CDK15 RNA expression.
This table summarizes CDK15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CDK15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK15 shows lower tumor expression in LUAD, LUSC, BLCA, COAD and KICH and higher tumor expression in HNSC. The LUAD box plot shows higher CDK15 RNA expression in normal versus tumor tissue (log2 FC = −0.633, t-test p < 0.001).
This table shows molecular features associated with CDK15 in patient tissues and cancer cell lines. In patient samples, CDK15 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
